Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC cut its holdings in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 40.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 64,900 shares of the company’s stock after selling 44,900 shares during the period. Renaissance Technologies LLC’s holdings in Vistagen Therapeutics were worth $226,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Acadian Asset Management LLC purchased a new stake in shares of Vistagen Therapeutics during the first quarter worth about $169,000. American Century Companies Inc. grew its stake in shares of Vistagen Therapeutics by 49.1% in the 2nd quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock valued at $105,000 after buying an additional 9,984 shares during the period. Finally, StemPoint Capital LP boosted its position in shares of Vistagen Therapeutics by 3.3% during the 1st quarter. StemPoint Capital LP now owns 1,848,582 shares of the company’s stock worth $9,292,000 after purchasing an additional 58,400 shares during the period. Hedge funds and other institutional investors own 78.39% of the company’s stock.

Vistagen Therapeutics Price Performance

Shares of NASDAQ:VTGN opened at $3.03 on Friday. The company’s fifty day moving average price is $3.24 and its 200 day moving average price is $3.83. Vistagen Therapeutics, Inc. has a 12 month low of $2.45 and a 12 month high of $5.86. The firm has a market capitalization of $81.89 million, a P/E ratio of -1.46 and a beta of 0.78.

Vistagen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06. The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.30 million. Vistagen Therapeutics had a negative net margin of 3,421.85% and a negative return on equity of 35.12%. During the same period in the previous year, the business posted ($0.94) earnings per share. On average, sell-side analysts anticipate that Vistagen Therapeutics, Inc. will post -1.79 EPS for the current year.

Analysts Set New Price Targets

Separately, William Blair raised shares of Vistagen Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.